Maximizing Efficacy and Minimizing Toxicity of ADCs Targeting HER2, HER3, and TROP-2: Strategies for Oncology Pharmacists

Get up to date on how oncology pharmacists can optimize care for patients receiving ADCs targeting HER2, HER3, and TROP-2 with downloadable slides, a frequently asked questions commentary, and an on-demand webcast capturing a live symposium at HOPA AC24. 

Share

Program Content

Activities

ADCs for Pharmacists
Maximizing Efficacy and Minimizing Toxicity of ADCs Targeting HER2, HER3, and TROP-2: Strategies for Oncology Pharmacists
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 04, 2024

Expires: April 03, 2025

Activities

ADC therapy strategies for oncology pharmacy
Maximizing Efficacy and Minimizing Toxicity of ADCs Targeting HER2, HER3, and TROP-2: Strategies for Oncology Pharmacists
Video
Congratulations: You achieved a completion on 04/09/2022

Released: April 17, 2024

Expires: April 16, 2025

Activities

ADCs for Pharmacists FAQs
Expert Answers to FAQs on HER2-, HER3-, and TROP-2–Directed ADCs for Pharmacists
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 23, 2024

Expires: April 22, 2025

Faculty

cover img faculity

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
UK Healthcare
Lexington, Kentucky

cover img faculity

Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP

Clinical Oncology Pharmacist, UI Health
Clinical Associate Professor
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

Provided by

ProCE Banner

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Clinical Care Options, LLC

ProCE Banner